AstraZeneca PLC (AZN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $286.07B
Last updated: Nov 17, 2026 at 11:05 AM ET
AstraZeneca PLC (AZN) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, AstraZeneca reported EPS of $2.79, above the $2.60 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
Analysts' consensus for the quarter ending Dec 31, 2026 is 63.1% above the $1.49 reported for the quarter ended Dec 31, 2025.
AZN's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
AZN Earnings Call
The latest AZN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 36 quarters below that had an estimate, AZN beat 24, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $15.99B, up 5.3% from $15.19B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.79 | $2.60 | N/A | +7.31% | Beat | +134.5% | 1 | 0 up, 0 down | Oct 30, 2026 | $15.99B |
| Jun 30, 2026 | $2.63 | $2.50 | N/A | +5.20% | Beat | +232.9% | 2 | 1 up, 0 down | Jul 27, 2026 | $15.38B |
| Mar 31, 2026 | $1.29 | $1.27 | $1.25 - $1.29 | +1.57% | Beat | +3.2% | 2 | 1 up, 0 down | Apr 29, 2026 | $15.29B |
| Dec 31, 2025 | $1.49 | $1.08 | $1.02 - $1.18 | N/A | N/A | +41.7% | 3 | 0 up, 1 down | Feb 10, 2026 | $15.50B |
| Sep 30, 2025 | $1.19 | $1.13 | $1.13 - $1.14 | +5.31% | Beat | +14.4% | 3 | 2 up, 1 down | Nov 6, 2025 | $15.19B |
| Jun 30, 2025 | $0.79 | $0.88 | N/A | -10.23% | Miss | -20.2% | 3 | 0 up, 2 down | Jul 29, 2025 | $14.46B |
| Mar 31, 2025 | $1.25 | $1.12 | $1.09 - $1.13 | +11.61% | Beat | +21.4% | 3 | 1 up, 0 down | Apr 29, 2025 | $13.59B |
| Mar 30, 2025 | $2.48 | $2.25 | N/A | +10.22% | Beat | +140.8% | N/A | N/A | Apr 29, 2025 | $13.59B |
| Dec 31, 2024 | $1.05 | $1.04 | N/A | +0.96% | Beat | +43.8% | N/A | N/A | Feb 6, 2025 | $14.89B |
| Sep 30, 2024 | $1.04 | $1.03 | $0.98 - $1.12 | +0.97% | Beat | +19.5% | 3 | 0 up, 0 down | Nov 12, 2024 | $13.56B |
| Jun 30, 2024 | $0.99 | $0.99 | $0.98 - $1.80 | 0.00% | In line | -8.3% | 4 | 1 up, 1 down | Jul 25, 2024 | $12.94B |
| Mar 31, 2024 | $1.03 | $0.95 | $0.93 - $1.79 | +8.42% | Beat | +7.3% | 3 | 2 up, 0 down | Apr 25, 2024 | $12.68B |
| Dec 31, 2023 | $0.73 | $0.76 | N/A | -3.95% | Miss | +5.8% | N/A | N/A | Feb 8, 2024 | $12.02B |
| Sep 30, 2023 | $0.87 | $0.82 | N/A | +6.10% | Beat | +3.6% | 1 | 0 up, 0 down | Nov 9, 2023 | $11.49B |
| Jun 30, 2023 | $1.08 | $0.97 | $0.83 - $1.03 | +11.34% | Beat | +25.6% | 3 | 0 up, 0 down | Jul 28, 2023 | $11.42B |
| Mar 31, 2023 | $0.96 | $0.82 | $0.82 - $1.75 | +17.07% | Beat | +1.1% | 4 | 1 up, 0 down | Apr 27, 2023 | $10.88B |
| Dec 31, 2022 | $0.69 | $0.68 | N/A | +1.47% | Beat | -17.9% | N/A | N/A | Feb 9, 2023 | $11.21B |
| Sep 30, 2022 | $0.84 | $0.75 | N/A | +12.00% | Beat | +55.6% | 1 | 0 up, 0 down | Nov 10, 2022 | $10.98B |
| Jun 30, 2022 | $0.86 | $1.04 | N/A | -17.31% | Miss | +91.1% | 1 | 0 up, 0 down | Jul 29, 2022 | $10.77B |
| Mar 31, 2022 | $0.95 | $1.15 | N/A | -17.39% | Miss | +15.9% | 1 | 0 up, 1 down | Apr 29, 2022 | $11.39B |
| Dec 31, 2021 | $0.84 | $0.99 | N/A | -15.15% | Miss | +37.7% | N/A | N/A | Feb 10, 2022 | $12.01B |
| Sep 30, 2021 | $0.54 | $0.46 | N/A | +18.68% | Beat | +17.4% | 2 | N/A | Nov 12, 2021 | $9.87B |
| Jun 30, 2021 | $0.45 | $0.35 | N/A | +30.43% | Beat | -6.2% | 1 | N/A | Jul 29, 2021 | $8.22B |
| Mar 31, 2021 | $0.82 | $0.96 | N/A | -14.58% | Miss | +54.7% | 1 | N/A | Apr 30, 2021 | $7.32B |
| Dec 31, 2020 | $0.61 | $0.76 | N/A | -19.74% | Miss | +155.7% | N/A | N/A | Feb 11, 2021 | $7.41B |
| Sep 30, 2020 | $0.46 | $0.48 | N/A | -4.17% | Miss | -8.0% | 1 | N/A | Nov 5, 2020 | $6.58B |
| Jun 30, 2020 | $0.48 | $0.40 | N/A | +20.00% | Beat | +29.7% | 1 | N/A | Jul 30, 2020 | $6.28B |
| Mar 31, 2020 | $0.53 | $0.49 | N/A | +8.16% | Beat | +17.8% | 1 | N/A | Apr 29, 2020 | $6.35B |
| Dec 31, 2019 | $0.24 | N/A | N/A | N/A | N/A | -70.8% | N/A | N/A | Feb 14, 2020 | $6.66B |
| Sep 30, 2019 | $0.50 | $0.41 | N/A | +21.95% | Beat | +38.9% | 1 | N/A | Oct 24, 2019 | $6.41B |
| Jun 30, 2019 | $0.37 | $0.31 | $0.28 - $0.31 | +19.35% | Beat | +5.7% | 2 | N/A | Jul 25, 2019 | $5.82B |
| Mar 31, 2019 | $0.45 | $0.38 | N/A | +18.42% | Beat | +67.7% | 3 | N/A | Apr 26, 2019 | $5.49B |
| Dec 31, 2018 | $0.82 | N/A | N/A | N/A | N/A | +25.6% | N/A | N/A | Feb 14, 2019 | $6.42B |
| Sep 30, 2018 | $0.36 | $0.37 | N/A | -2.70% | Miss | -35.7% | N/A | N/A | Nov 8, 2018 | $5.34B |
| Jun 30, 2018 | $0.35 | $0.30 | N/A | +16.67% | Beat | -20.5% | 2 | N/A | Jul 26, 2018 | $5.16B |
| Mar 31, 2018 | $0.27 | $0.35 | $0.29 - $0.42 | N/A | N/A | -46.3% | 3 | N/A | May 18, 2018 | $5.18B |
| Dec 31, 2017 | $0.65 | $0.56 | N/A | +16.07% | Beat | +6.6% | N/A | N/A | Feb 2, 2018 | $5.78B |
| Sep 30, 2017 | $0.56 | $0.57 | $0.49 - $0.63 | -1.75% | Miss | -15.2% | 3 | N/A | Nov 9, 2017 | $6.23B |
| Jun 30, 2017 | $0.44 | $0.42 | $0.42 - $0.42 | +4.76% | Beat | +4.8% | 2 | N/A | Jul 27, 2017 | $5.05B |
| Mar 31, 2017 | $0.50 | $0.54 | N/A | -7.41% | Miss | +4.2% | 1 | N/A | Apr 27, 2017 | $5.41B |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $4.72, up 14.8% from the year before. It was $2.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $4.72 | +14.8% |
| Dec 31, 2024 | $4.11 | +12.9% |
| Dec 31, 2023 | $3.64 | +9.0% |
| Dec 31, 2022 | $3.34 | +26.0% |
| Dec 31, 2021 | $2.65 | +27.4% |
| Dec 31, 2020 | $2.08 | +33.5% |
| Dec 31, 2019 | $1.56 | -13.1% |
| Dec 31, 2018 | $1.79 | -16.5% |
| Dec 31, 2017 | $2.15 | N/A |
| Dec 31, 2016 | $2.17 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 15,000 words across 23 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 14,811 | 23 | |
| 2026Q2 | Jun 30, 2026 | 13,448 | 24 | |
| 2026Q1 | Mar 31, 2026 | 10,414 | 24 | |
| 2025Q4 | Dec 31, 2025 | 7,591 | 15 | |
| 2025Q3 | Sep 30, 2025 | 8,993 | 23 | |
| 2025Q2 | Jun 30, 2025 | 10,198 | 17 | |
| 2025Q1 | Mar 31, 2025 | 5,421 | 10 | |
| 2024Q4 | Dec 31, 2024 | 6,012 | 10 |
2026Q3 Earnings Call
Opening remarks
Joris Silon Head of Investor Relations A warm welcome to AstraZeneca's 9 Months and Third Quarter 2026 Presentation Conference Call and Webcast for Investors and Analysts. I'm Joris Silon, Head of Investor Relations. And before I hand over to Pascal and members of our executive team, I would like to cover some housekeeping items. All of the materials presented today are available on our AstraZeneca Investor Relations website. Next slide, please. This slide contains our forward-looking statements, including the safe harbor provisions, which I would encourage you to take the time to read. We will be making comments on our performance using constant exchange rates, or CER, or financial numbers and other non-GAAP measures. A non-GAAP to GAAP reconciliation is contained within the results announcement. All numbers quoted are in millions of U.S. dollars unless stated otherwise. Next slide, please. This slide shows our agenda for today's call. Following our prepared remarks, we will open the line for questions. And as usual, we will try to address as many questions as we can during the allocated time. Although please limit the number of questions you ask to allow others a fair chance to participate in the Q&A. And with that, please advance to the next slide, and Pascal, over to you.
Pascal Soriot CEO Thank you, Joris, and welcome, everybody. Next slide, please. I'm pleased to report that our strong growth momentum and pipeline delivery have continued through the first 9 months of 2026. This reflects the progress we are making across our strategic priorities and overall, the focus and the commitment of teams across our company. Total revenue grew 7% and core EPS increased 14%. Excluding Farxiga and Brilinta, total revenue grew 12%, demonstrating the underlying strength of our broad portfolio. Since our full year results in February, we've announced positive results from 12 Phase III programs, and we've achieved first approvals for 4 new medicines, including Etcamah in the U.S. This brings our total number of approved new molecular entities to 14 as we progress towards our goal of delivering 20 new medicines by 2030. We've also presented positive Phase III data for 3 new molecular entities: tozorakimab in COPD, efzimfotase alfa in HPP and sone-ve, our first wholly owned ADC, in Claudin 18.2 positive gastric cancer. With commercial momentum continuing and a deep late-stage pipeline advancing, we are increasingly confident in our ability to deliver our 2030 ambition as well as sustainable long-term growth through the next decade. Next slide, please. Our strong performance is underpinned by the breadth of our therapy areas and our geographical footprint. In the first 9 months, oncology, rare disease and R&I all delivered double-digit growth.
Frequently Asked Questions About AZN
Did AZN beat earnings estimates last quarter?
Yes. AstraZeneca reported EPS of $2.79 for the quarter ended Sep 30, 2026, above the $2.60 estimate, a 7.31% surprise.
What EPS do analysts expect from AZN next quarter?
The consensus EPS estimate for AstraZeneca for the quarter ending Dec 31, 2026 is $2.43 from 18 analysts, with estimates from $2.09 to $2.72.
How often does AZN beat earnings estimates?
AstraZeneca beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +3.99%.
AZN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts